Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes - 04/11/26

Doi : 10.1016/j.tjpad.2026.100691

Yu-Hsin Yen ^a,^{^{1
Yu-Hsin Yen and Fu-Shun Yen contributed equally in this work.}} , James Cheng-Chung Wei ^b,^c,^d , Yao-Min Hung ^r,^s,^t,^u , Shih-Yi Lin ^e , Fu-Shun Yen ^f,^{^{1
Yu-Hsin Yen and Fu-Shun Yen contributed equally in this work.}} , Heng-Jun Lin ^g,^h , Yu-Han Huang ^g,^h , Der-Yang Cho ^i,^j,^k , Chii-Min Hwu ^l,^m,^⁎ , Chih-Cheng Hsu ^n,^o,^p,^q,^⁎

^a Duke-NUS Medical School, 8 College Rd, Singapore, 169857, Singapore

^b Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, No. 110, Sec. 1, Jianguo N. Rd., South District, Taichung City, 40201, Taiwan

^c Institute of Medicine, Chung Shan Medical University, Taichung City, 40201, Taiwan

^d Graduate Institute of Integrated Medicine, China Medical University, Taichung, 40402, Taiwan

^e Division of Endocrinology and Metabolism, Taichung Veterans General Hospital, 160, Sec. 3, Taichung-Kang Road, Taichung, 407, Taiwan

^f Dr. Yen’s Clinic, No. 15, Shanying Road, Gueishan District, Taoyuan, 33354, Taiwan

^g Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

^h College of Medicine, China Medical University, Taichung, Taiwan

ⁱ Translational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, 404327, Taiwan

^j Department of Neurosurgery, China Medical University Hospital, Taichung, 404327, Taiwan

^k Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 404327, Taiwan

^l Faculty of Medicine, National Yang Ming Chiao Tung University School of Medicine, No.155, Sec.2, Linong Street, Taipei, 11221, Taiwan

^m Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, No.201, Sec. 2, Shipai Road, Beitou District, Taipei, 11217, Taiwan

ⁿ Institute of Population Health Sciences, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County, 35053, Taiwan

^o Department of Health Services Administration, China Medical University, Taichung, 40402, Taiwan

^p Department of Family Medicine, Min-Sheng General Hospital, 168 ChingKuo Road, Taoyuan, 33044, Taiwan

^q National Center for Geriatrics and Welfare Research, National Health Research Institutes, No. 95-1, Xuefu Rd., Huwei Township, Yunlin County, 632007, Taiwan

^r Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

^s College of Health and Nursing, Meiho University, Pingtung, Taiwan

^t Master Program in Biomedicine, College of Science and Engineering, National Taitung University, Taitung, Taiwan

^u Fooyin University College of Nursing, Kaohsiung, Taiwan

^⁎ Corresponding author at: Institute of Population Health Sciences, National Health Research Institutes. Institute of Population Health Sciences National Health Research Institutes. ^⁎⁎ Corresponding author at: Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital. Section of Endocrinology and Metabolism Department of Medicine Taipei Veterans General Hospital.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Introduction

Dementia risk is significantly amplified by type 2 diabetes (T2D). This study compares the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2is) against pioglitazone, dipeptidyl peptidase-4 inhibitors (DPP-4is), and sulfonylureas on dementia risk.

Methods

Using Taiwan’s National Health Insurance Research Database (2000–2021), researchers emulated target trials with propensity-score matching. Cox proportional-hazards and Kaplan-Meier analyses estimated adjusted hazard ratios (aHRs) for dementia subtypes.

Results

Over a mean follow-up of 2.9 years, SGLT2i users had significantly lower cumulative incidences of all-cause and vascular dementia (all log-rank p   <  0.05). Compared to pioglitazone, SGLT2i use was associated with lower risks of all-cause dementia (aHR 0.78, 95% CI 0.73–0.83) and vascular dementia (aHR 0.83, 95% CI 0.69–0.99). Alzheimer's risk reductions were not statistically significant.

Discussion

In these nationwide emulated trials, SGLT2is were associated with lower risks of all-cause and vascular dementia compared with pioglitazone, DPP-4is, and sulfonylureas.

Le texte complet de cet article est disponible en PDF.

Key words : All-cause dementia, Alzheimer’s disease, Vascular dementia, Sodium–glucose cotransporter-2 inhibitors, Pioglitazone, Dipeptidyl peptidase-4 inhibitors, Sulfonylureas, Type 2 diabetes

Abbreviations : T2D, SGLT2is, DPP-4is, GLP-1 RAs, ACEI, ARB

Plan

Export

Vol 13 - N° 10

Article 100691- décembre 2026 Retour au numéro

Article précédent

CSF pTau181 predicts asymmetric hippocampal atrophy in cognitively unimpaired older adults
Elham Ghanbarian, Lukai Zheng, Tianchen Qian, Crystal M. Glover, S. Ahmad Sajjadi, Maria M. Corrada, Joshua D. Grill, Ali Ezzati, Alzheimer’s Disease Neuroimaging Initiative

| Article suivant

Survival analysis of spontaneous speech for predicting mild cognitive impairment-to-dementia conversion
Adrián Hinojosa-Calleja, Berta Calm, Montserrat Alegret, Ana Espinosa, Amanda Cano, Maria Victoria Fernández, Andrea Miguel, Ariadna Solivar, Alejandro Valenzuela-Seba, Pablo García-González, Raquel Puerta, Clàudia Olivé, Maria Capdevila-Bayo, Álvaro Muñoz-Morales, Paula Bayón-Buján, Marta Rovira-Bruna, Maider Iza, Laura Montreal, Maitee Rosende-Roca, Pilar Sanz-Cartagena, Yahveth Cantero-Fortiz, Miren Jone Gurruchaga, Lluis Tarraga, Xavier Montalbán, Mercè Boada, Agustín Ruiz, Marta Marquié, Sergi Valero

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes - 04/11/26

Abstract

Introduction

Methods

Results

Discussion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL